Logo image of QURE

UNIQURE NV (QURE) Stock Fundamental Analysis

NASDAQ:QURE - Nasdaq - NL0010696654 - Common Stock - Currency: USD

13  +3.61 (+38.45%)

After market: 13.24 +0.24 (+1.85%)

Fundamental Rating

3

Overall QURE gets a fundamental rating of 3 out of 10. We evaluated QURE against 568 industry peers in the Biotechnology industry. QURE has a bad profitability rating. Also its financial health evaluation is rather negative. QURE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

QURE had negative earnings in the past year.
In the past year QURE has reported a negative cash flow from operations.
QURE had negative earnings in 4 of the past 5 years.
QURE had negative operating cash flow in 4 of the past 5 years.
QURE Yearly Net Income VS EBIT VS OCF VS FCFQURE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

The Return On Assets of QURE (-43.04%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -43.04%
ROE N/A
ROIC N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QURE Yearly ROA, ROE, ROICQURE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

QURE has a better Gross Margin (32.42%) than 73.77% of its industry peers.
In the last couple of years the Gross Margin of QURE has declined.
The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
QURE Yearly Profit, Operating, Gross MarginsQURE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
QURE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for QURE has been increased compared to 5 years ago.
Compared to 1 year ago, QURE has a worse debt to assets ratio.
QURE Yearly Shares OutstandingQURE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
QURE Yearly Total Debt VS Total AssetsQURE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -2.34, we must say that QURE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.34, QURE perfoms like the industry average, outperforming 54.05% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.34
ROIC/WACCN/A
WACC6.83%
QURE Yearly LT Debt VS Equity VS FCFQURE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 9.74 indicates that QURE has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.74, QURE is doing good in the industry, outperforming 79.05% of the companies in the same industry.
A Quick Ratio of 9.74 indicates that QURE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.74, QURE is doing good in the industry, outperforming 79.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 9.74
QURE Yearly Current Assets VS Current LiabilitesQURE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

8

3. Growth

3.1 Past

QURE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.62%, which is quite impressive.
QURE shows a strong growth in Revenue. In the last year, the Revenue has grown by 71.68%.
The Revenue has been growing by 30.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)23.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.72%
Revenue 1Y (TTM)71.68%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%-21.95%

3.2 Future

The Earnings Per Share is expected to grow by 26.26% on average over the next years. This is a very strong growth
QURE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 81.90% yearly.
EPS Next Y19.58%
EPS Next 2Y15.87%
EPS Next 3Y12.55%
EPS Next 5Y26.26%
Revenue Next Year11.98%
Revenue Next 2Y84%
Revenue Next 3Y48.88%
Revenue Next 5Y81.9%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
QURE Yearly Revenue VS EstimatesQURE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
QURE Yearly EPS VS EstimatesQURE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QURE. In the last year negative earnings were reported.
Also next year QURE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QURE Price Earnings VS Forward Price EarningsQURE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QURE Per share dataQURE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

QURE's earnings are expected to grow with 12.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.87%
EPS Next 3Y12.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QURE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNIQURE NV

NASDAQ:QURE (4/17/2025, 8:00:00 PM)

After market: 13.24 +0.24 (+1.85%)

13

+3.61 (+38.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners77.83%
Inst Owner Change0.61%
Ins Owners1.69%
Ins Owner Change2.66%
Market Cap703.04M
Analysts84.21
Price Target36.82 (183.23%)
Short Float %5.25%
Short Ratio2.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-64.14%
Min EPS beat(2)-139.62%
Max EPS beat(2)11.35%
EPS beat(4)2
Avg EPS beat(4)-30.76%
Min EPS beat(4)-139.62%
Max EPS beat(4)11.35%
EPS beat(8)2
Avg EPS beat(8)-60.1%
EPS beat(12)5
Avg EPS beat(12)-28.25%
EPS beat(16)8
Avg EPS beat(16)-0.67%
Revenue beat(2)0
Avg Revenue beat(2)-69.18%
Min Revenue beat(2)-71.35%
Max Revenue beat(2)-67%
Revenue beat(4)2
Avg Revenue beat(4)-11.63%
Min Revenue beat(4)-71.35%
Max Revenue beat(4)58.38%
Revenue beat(8)3
Avg Revenue beat(8)-38.12%
Revenue beat(12)4
Avg Revenue beat(12)-16.17%
Revenue beat(16)6
Avg Revenue beat(16)15.04%
PT rev (1m)-1.37%
PT rev (3m)13.78%
EPS NQ rev (1m)-1.68%
EPS NQ rev (3m)-28.18%
EPS NY rev (1m)-15.61%
EPS NY rev (3m)-17.52%
Revenue NQ rev (1m)6.76%
Revenue NQ rev (3m)-0.97%
Revenue NY rev (1m)24.14%
Revenue NY rev (3m)26.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.95
EYN/A
EPS(NY)-3.98
Fwd EYN/A
FCF(TTM)-3.44
FCFYN/A
OCF(TTM)-3.38
OCFYN/A
SpS0.5
BVpS-0.12
TBVpS-1.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.04%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.42%
FCFM N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.64%
Cap/Sales 12.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 9.74
Altman-Z -2.34
F-Score4
WACC6.83%
ROIC/WACCN/A
Cap/Depr(3y)98.33%
Cap/Depr(5y)124.6%
Cap/Sales(3y)24.73%
Cap/Sales(5y)20.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.72%
EPS Next Y19.58%
EPS Next 2Y15.87%
EPS Next 3Y12.55%
EPS Next 5Y26.26%
Revenue 1Y (TTM)71.68%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%-21.95%
Revenue Next Year11.98%
Revenue Next 2Y84%
Revenue Next 3Y48.88%
Revenue Next 5Y81.9%
EBIT growth 1Y37.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.12%
EBIT Next 3Y6.1%
EBIT Next 5Y49.92%
FCF growth 1Y-21.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.22%
OCF growth 3YN/A
OCF growth 5YN/A